葡萄糖皮质体受体-NECAB1轴可以负面调节胰腺β细胞中的胰岛素分泌
Haruhide Udagawa1,2, Nobuaki Funahashi3, Wataru Nishimura4,5
1Department of Metabolic Disorder, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, 162-8655, Japan.
Scientific reports
|October 20, 2023
概括
脂肪细胞衍生因素,包括像皮质醇这样的类固醇激素,通过增加NECAB1,胰腺β细胞功能,增加胰岛素分泌的负调节者. 这一发现揭示了与肥胖相关的糖尿病机制.
科学领域:
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
- 代谢疾病 代谢疾病
背景情况:
- 肥胖会损害胰腺β细胞功能和胰岛素分泌,但潜在的机制尚不清楚.
- 脂肪细胞衍生因素与代谢失调有关,但它们对β细胞的特定影响需要进一步研究.
研究的目的:
- 研究脂肪细胞衍生因素对胰腺β细胞功能的影响.
- 阐明特定脂肪细胞因子及其信号通路在受损胰岛素分泌中的作用.
主要方法:
- 使用来自3T3-L1脂肪细胞 (D8CM) 的条件介质来治疗INS-1D大鼠胰腺β细胞.
- 分析了胰岛素分泌,细胞内水平和Necab1 mRNA表达.
- 使用液体染色学-质谱/质谱 (LC-MS/MS) 来识别类固醇激素.
- 研究了葡萄糖皮质体受体 (GR) 的作用及其与Necab1促进体区域的结合.
主要成果:
- D8CM通过减少细胞内来抑制INS-1D细胞中的胰岛素分泌.
- 确定NECAB1 (胰岛素分泌的负调节剂) 是一个关键的调解者.
- 在D8CM中,类固醇激素 (皮质醇,皮质) 增加了Necab1的表达,减少了胰岛素的分泌.
- 抑制葡萄糖皮质体受体 (GR) 消除了这些荷尔蒙效应.
- 在db/db小鼠的胰腺小岛中观察到NECAB1的增加表达,依赖于GR激活并与Necab1上游区域结合.
结论:
- 来自脂肪细胞的类固醇激素通过葡萄糖皮质体受体起作用,在胰腺β细胞上调节NECAB1的表达.
- 这种机制导致胰岛素分泌受损,并可能在与肥胖相关的糖尿病病理生理学中发挥重要作用.
- 在脂肪岛轴上,NECAB1成为一个新的参与者,将脂肪组织功能障碍与肥胖中的β细胞衰竭联系起来.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334


